(“CR”) rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T ...
Long before India emerged as one of the world’s leading sugar producers, its fields told a different story. Farmers ...
A single cilta-cel infusion after fludarabine/cyclophosphamide produced 100% MRD negativity at 10⁻⁶ by month 2, sustained at ...
Detailed price information for Tempest Therapeutics Inc (TPST-Q) from The Globe and Mail including charting and trades.
New chromosome-level evidence suggests Medicago evolution followed a more complex, and surprising path, than previously ...
LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA failure and high-risk cytogenetics. Across 101 treated patients, no ...
Emerging opportunities in the cancer biomarkers market include the growth of personalized oncology, non-invasive diagnostics, ...
Detailed price information for Tempest Therapeutics Inc (TPST-Q) from The Globe and Mail including charting and trades.
1 Histology-Embryology-Cytogenetics Laboratory, UFR-Medical Sciences, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire. 2 Laboratory of Physiology, Pharmacology and Pharmacopoeia, UFR-Nature ...
In the Department of Genetics, doctors are using genetic and genomic testing to pinpoint the exact cause of a patient’s condition—even when symptoms mimic more than one disorder. This clarity is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results